Developing and Improving Access to New Products for Diseases with no Treatments
Chugai will create and develop innovative products for unmet medical needs, such as treatments for diseases that currently have no cure, by using its drug discovery technology centered on biotechnologies obtained through its research and development.
These products are only meaningful when they reach the people who need them. We are contributing to improving access to medicines not only in developed countries but also in developing countries by leveraging our strengths in various disease-specialized areas and technologies.
WFH Aid program
Chugai cooperates with the World Federation of Hemophilia (WFH) to provide the medicine we created to hemophilia patients in developing countries where access to treatment is extremely limited. Chugai attempts to improve treatment access including medical equipment and education for healthcare professionals with Roche.
Industry-government-academia collaboration for Rheumatoid medicine
Through industry-government-academia collaboration, Chugai contributes to the realization and quality improvement of sustainable rheumatology care in Indonesia.
Development Project for Anti-Dengue Virus Antibody
Chugai is conducting the research and development of therapeutic agents that utilize antibody technology to treat dengue fever, one of the neglected tropical diseases that prevail in developing countries.
Improving Access to Sustainable Healthcare
Access to healthcare is a complex challenge and there are no one-size-fits-all solutions. As access barriers vary widely depending on the country or region, it is important to identify local needs and region-specific barriers, and then develop and implement appropriate plans. By collaborating and cooperating with various public institutions, NGOs, patient associations, and pharmaceutical companies, we contribute to the improvement of sustainable health care systems, mainly in low- and middle-income countries.
Non-Communicable Diseases (NCDs)
We cooperate with NGOs to carry out support activities that meet local needs. In addition, in order to achieve solutions to issues where individual companies have limitations, we launched the industry partnership called Access Accelerated together with more than 20 global pharmaceutical companies for the prevention, diagnosis, and treatment of non-communicable diseases (NCDs) in low- and middle-income countries. Furthermore, AA has developed a method to measure and evaluate the effects and impact of individual activities in cooperation with a third-party organization. By aggregating and sharing the results of each activity, we aim to establish a mechanism to review and improve its activities.
Healthcare challenges are multifaceted, and improving one aspect of healthcare is often not enough. In particular, for complex treatments such as cancer, improvements in various fields are required for successful treatment, such as diagnosis, specialized training, and hospital infrastructure. Through partnerships with the City Cancer Challenge and Japan Heart, we leverage the accumulated know-how and experience of patient-centered multidisciplinary team care in Japan to contribute to improving the medical infrastructure of cancer care, which is Chugai’s expertise.
Infectious Disease Area
We joined the GHIT Fund, a public-private partnership, to support the research and development of medicines, vaccines, and diagnostics for serious infectious diseases in developing countries by leveraging Japan’s medical technology, innovation, and knowledge. In addition, in order to combat infectious diseases caused by antimicrobial resistance, which is rapidly increasing throughout the world, we joined the AMR Action Fund and provide investment and technical support to small-scale biotechnology companies working on the development of innovative antimicrobial drugs.
Points Considered for Individual Activities and the Verification/Follow-up Cycle
Chugai values the following points in determining the global health activities it will support and implement.
- Activities in which Chugai’s strength, technology, or expertise can be utilized
- Activities that can contribute to the sustainable improvement of healthcare, mainly in low- and middle- income countries
Through these activities, we will implement the verification/follow-up cycle based on local needs as we aim to realize our vision of becoming a Top Innovator in 2030 by both resolving social issues and improving corporate value.